ACTnet TB Journal Club | 4-Month TB Regimen Trial with Dr Glyzelle Lagason

The ACTnet Asia-Pacific Regional TB Journal Club was held on Tuesday 28 July at 1:00 pm AEST and featured guest speaker Dr Glyzelle Lagason. Dr Glyzelle Lagason is a physician and Medical Research Investigator at TBHIV Innovations and Clinical Research Foundation Corp in the Philippines, where she works on clinical studies in tuberculosis (TB), HIV, and malnutrition. Alongside her research, she practices primary care and is committed to translating clinical evidence into everyday healthcare, with interests in TB, HIV, vaccination, and implementation research. During the session, Glyzelle discussed the paper: Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial - https://pubmed.ncbi.nlm.nih.gov/42214... The paper evaluated whether a 4-month DBQ regimen could safely and effectively shorten treatment for drug-susceptible TB compared with the standard 6-month RHEZ regimen, finding it to be effective and well tolerated.